Clinical trials
Advance Solid Tumors clinical trials
Below are recruiting advance solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,378 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05270213RecruitingPhase 1
RBS2418 for advanced cancers after standard treatments
This early-phase study tests RBS2418 in people with advanced, metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or help control disease, and to learn what doses are safest.
Scottsdale, ArizonaAges 18 years+ - NCT05329103RecruitingPhase 1
Test drug PEEL-224 in advanced solid tumor cancers
This Phase 1 study tests PEEL-224 in people whose solid tumors are advanced and have not responded to standard treatments (or have no approved standard option). It focuses on safety and early signs of whether the drug can help shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT05267912Recruiting
Using tumor organoids to guide treatment for advanced cancers
This study tests whether growing a patient's tumor cells in a dish (called an organoid) can help doctors choose the best next treatment. It is for people with advanced colorectal or pancreatic cancer who have run out of standard options.
Bordeaux, FranceAges 18 years+ - NCT05272709RecruitingPhase 1/Phase 2
New pill TT-702 for advanced solid tumors
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
LondonAges 16 years+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT05277168RecruitingPhase 1/Phase 2
Study drug for advanced stomach or pancreatic cancer with Claudin 18.2
This trial tests the safety and side effects of SHR-A1904, and whether it can help people with advanced stomach or pancreatic cancer. To join, your tumor must have high “Claudin 18.2” protein, and you must meet several health and timing requirements.
Miami Beach, FloridaAges 18 years+ - NCT05262491RecruitingPhase 1
Early drug study for advanced GI or solid cancers that failed treatment
This Phase 1 trial tests BL-B01D1, a new cancer medicine, in people with advanced or metastatic gastrointestinal or other solid tumors that did not respond to standard treatment (or cannot use standard treatment). It also looks at whether a tumor marker called TROP2 may help predict who benefits.
Beijing, Beijing MunicipalityAges 18–75 - NCT05259709RecruitingPhase 1
Imaging test to map tumors in cancers on PD-1 therapy
This Phase 1 study tests a special imaging medicine to see how tumors and immune activity respond when you’re treated with cemiplimab (a PD-1 immunotherapy). It may help doctors better understand who benefits from PD-1 treatment by tracking where the medicine goes in the body.
GroningenAges 18 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Phoenix, ArizonaAges 18 years+ - NCT05245058RecruitingEarly Phase 1
SPH5030 for HER2-positive advanced solid tumors
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
Hefei, AnhuiAges 18 years+ - NCT05170958RecruitingPhase 1/Phase 2
Study of LBL-024 for advanced cancers
This trial tests LBL-024 in people with advanced cancer to see how it works and how safe it is. You may consider it if you are well enough for study visits and have time to complete at least about 12 weeks of follow-up.
Hefei, AnhuiAges 18–80 - NCT05150691RecruitingPhase 1/Phase 2
Early study of an HER2 drug in advanced solid tumors
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Cerritos, CaliforniaAges 18 years+ - NCT05194982RecruitingPhase 1
Early study drug BL-B01D1 for advanced solid tumors
This Phase 1 trial tests BL-B01D1 in people with advanced or metastatic solid tumors that are not curable or lack standard treatment options. The goal is to see how the drug works in the body and whether it’s safe enough to study further.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05156203RecruitingPhase 1
T-1301 capsule study for advanced solid tumors
This trial tests a new oral drug, T-1301, for people with advanced solid tumors (including lymphoma) that have stopped responding to standard treatments. The study aims to find a safe dose and see how the body responds.
Kaohsiung CityAges 20 years+ - NCT05166694Recruiting
Personalized testing to check drug interactions and gene effects
This study uses personalized information to help understand how your current medicines interact with each other and with your genes. It may help your care team choose safer, more effective medication plans for you.
Chicago, IllinoisAges 18 years+ - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Tucson, ArizonaAges 18 years+ - NCT05101070RecruitingPhase 1/Phase 2
Study of an anti-cancer drug alone or with immunotherapy
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Los Angeles, CaliforniaAges 18 years+ - NCT05087745RecruitingEarly Phase 1
TIL therapy for advanced solid tumors
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
Hangzhou, ZhejiangAges 18–75 - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Orange, CaliforniaAges 12 years+ - NCT05103683RecruitingPhase 1
First-time test of TORL-1-23 for advanced solid tumors
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
Fullerton, CaliforniaAges 18 years+ - NCT05067283RecruitingPhase 1
Study of Calderasib for KRAS G12C advanced cancers
This trial tests a new drug, Calderasib, for people with advanced solid tumors that have a specific mutation called KRAS G12C. It may help if your cancer has not responded to previous treatments or if you have certain types of lung or colorectal cancer.
Tampa, FloridaAges 18 years+
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advance solid tumors?
- Yes. Clin2 currently lists 1,378 recruiting advance solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advance solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advance solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.